Artificial intelligence for dementia research methods optimization.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published Date:

Abstract

Artificial intelligence (AI) and machine learning (ML) approaches are increasingly being used in dementia research. However, several methodological challenges exist that may limit the insights we can obtain from high-dimensional data and our ability to translate these findings into improved patient outcomes. To improve reproducibility and replicability, researchers should make their well-documented code and modeling pipelines openly available. Data should also be shared where appropriate. To enhance the acceptability of models and AI-enabled systems to users, researchers should prioritize interpretable methods that provide insights into how decisions are generated. Models should be developed using multiple, diverse datasets to improve robustness, generalizability, and reduce potentially harmful bias. To improve clarity and reproducibility, researchers should adhere to reporting guidelines that are co-produced with multiple stakeholders. If these methodological challenges are overcome, AI and ML hold enormous promise for changing the landscape of dementia research and care. HIGHLIGHTS: Machine learning (ML) can improve diagnosis, prevention, and management of dementia. Inadequate reporting of ML procedures affects reproduction/replication of results. ML models built on unrepresentative datasets do not generalize to new datasets. Obligatory metrics for certain model structures and use cases have not been defined. Interpretability and trust in ML predictions are barriers to clinical translation.

Authors

  • Magda Bucholc
    Cognitive Analytics Research Lab, School of Computing, Engineering & Intelligent Systems, Ulster University, Derry, UK.
  • Charlotte James
    University of Exeter Medical School, Exeter, United Kingdom.
  • Ahmad Al Khleifat
    Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • AmanPreet Badhwar
    Multiomics Investigation of Neurodegenerative Diseases (MIND) Lab, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.
  • Natasha Clarke
    Multiomics Investigation of Neurodegenerative Diseases (MIND) Lab, Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada.
  • Amir Dehsarvi
    Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences, and Nutrition, University of Aberdeen, Aberdeen, UK.
  • Christopher R Madan
    School of Psychology, University of Nottingham, Nottingham, UK.
  • Sarah J Marzi
    UK Dementia Research Institute, Imperial College London, London, UK.
  • Cameron Shand
    The Hartree Centre, Sci-Tech Daresbury, IBM Research, Daresbury, WA4 4AD, UK.
  • Brian M Schilder
    UK Dementia Research Institute, Imperial College London, London, UK.
  • Stefano Tamburin
    Neurology Section, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Hanz M Tantiangco
    Information School, University of Sheffield, Sheffield, UK.
  • Ilianna Lourida
    University of Exeter Medical School, Exeter, UK.
  • David J Llewellyn
    University of Exeter Medical School, Exeter, United Kingdom.
  • Janice M Ranson
    University of Exeter Medical School, Exeter, United Kingdom.